T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018
SUMMARY
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 21 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 6 and 3 respectively.
Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Central Nervous System, Cardiovascular and Gastrointestinal which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Systemic Lupus Erythematosus, Autoimmune Disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Encephalitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Psoriasis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox and West Nile Virus Infections.
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 21 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 6 and 3 respectively.
Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Central Nervous System, Cardiovascular and Gastrointestinal which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Systemic Lupus Erythematosus, Autoimmune Disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Encephalitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Psoriasis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox and West Nile Virus Infections.
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
- The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Evotec AG
Immupharma Plc
TaiMed Biologics Inc
United Biomedical Inc
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD4 and gp120 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target CD4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAX-16H5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD4 for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441236 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tregalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
Featured News & Press Releases
Oct 30, 2018: Trogarzo phase III data analysis presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study
Oct 29, 2018: United States Department of Health and Human Services publishes new HIV Treatment guidelines including Trogarzo
Oct 03, 2018: Pharmacokinetic profile of Trogarzo presented at IDWeek
Aug 28, 2018: Theratechnologies files marketing authorization application for Trogarzo in Europe
Aug 15, 2018: New HIV therapy reduces virus, boosts immunity in drug-resistant patients
Aug 15, 2018: the New England Journal of Medicine publishes two articles about Trogarzo
Jul 31, 2018: European Medicines Agency confirms accelerated assessment procedure for Trogarzo
Jul 25, 2018: Trogarzo included in most recent treatment guidelines issued by International Antiviral Society
Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
May 29, 2018: Further Analysis from its Pivotal Phase III Trial of Lupuzor in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort
May 23, 2018: Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo
May 16, 2018: Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status
Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.
Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference
Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Evotec AG
Immupharma Plc
TaiMed Biologics Inc
United Biomedical Inc
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD4 and gp120 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target CD4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAX-16H5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD4 for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441236 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tregalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
Featured News & Press Releases
Oct 30, 2018: Trogarzo phase III data analysis presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study
Oct 29, 2018: United States Department of Health and Human Services publishes new HIV Treatment guidelines including Trogarzo
Oct 03, 2018: Pharmacokinetic profile of Trogarzo presented at IDWeek
Aug 28, 2018: Theratechnologies files marketing authorization application for Trogarzo in Europe
Aug 15, 2018: New HIV therapy reduces virus, boosts immunity in drug-resistant patients
Aug 15, 2018: the New England Journal of Medicine publishes two articles about Trogarzo
Jul 31, 2018: European Medicines Agency confirms accelerated assessment procedure for Trogarzo
Jul 25, 2018: Trogarzo included in most recent treatment guidelines issued by International Antiviral Society
Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
May 29, 2018: Further Analysis from its Pivotal Phase III Trial of Lupuzor in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort
May 23, 2018: Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo
May 16, 2018: Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status
Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.
Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference
Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Biotest AG, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CEL-SCI Corp, H2 2018
Pipeline by Evotec AG, H2 2018
Pipeline by Immupharma Plc, H2 2018
Pipeline by TaiMed Biologics Inc, H2 2018
Pipeline by United Biomedical Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Biotest AG, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CEL-SCI Corp, H2 2018
Pipeline by Evotec AG, H2 2018
Pipeline by Immupharma Plc, H2 2018
Pipeline by TaiMed Biologics Inc, H2 2018
Pipeline by United Biomedical Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Evotec AG
Immupharma Plc
TaiMed Biologics Inc
United Biomedical Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Biotest AG
Bristol-Myers Squibb Co
CEL-SCI Corp
Evotec AG
Immupharma Plc
TaiMed Biologics Inc
United Biomedical Inc
